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Abstract
BACKGROUND: Multiple sclerosis (MS) likely results from an imbalance between
regulatory and inflammatory immune processes. CD39 is an ectoenzyme that
cleaves ATP to AMP and has been suggested as a novel regulatory T cells
(Treg) marker. As ATP has numerous proinflammatory effects, its degradation
by CD39 has anti-inflammatory influence. The purpose of this study was to
explore regulatory and inflammatory mechanisms activated in fingolimod treated
MS patients. METHODS AND FINDINGS: Peripheral blood mononuclear cells
(PBMCs) were isolated from relapsing-remitting MS patients before starting
fingolimod and three months after therapy start. mRNA expression was assessed
in ex vivo PBMCs. The proportions of CD8, B cells, CD4 and CD39-expressing
cells were analysed by flow cytometry. Treg proportion was quantified by
flow cytometry and methylation-specific qPCR. Fingolimod treatment increased
mRNA levels of CD39, AHR and CYP1B1 but decreased mRNA expression of
IL-17, IL-22 and FOXP3 mRNA in...
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Abstract
Background: Multiple sclerosis (MS) likely results from an imbalance between regulatory and inflammatory immune
processes. CD39 is an ectoenzyme that cleaves ATP to AMP and has been suggested as a novel regulatory T cells (Treg)
marker. As ATP has numerous proinflammatory effects, its degradation by CD39 has anti-inflammatory influence. The
purpose of this study was to explore regulatory and inflammatory mechanisms activated in fingolimod treated MS patients.
Methods and Findings: Peripheral blood mononuclear cells (PBMCs) were isolated from relapsing-remitting MS patients
before starting fingolimod and three months after therapy start. mRNA expression was assessed in ex vivo PBMCs. The
proportions of CD8, B cells, CD4 and CD39-expressing cells were analysed by flow cytometry. Treg proportion was
quantified by flow cytometry and methylation-specific qPCR. Fingolimod treatment increased mRNA levels of CD39, AHR
and CYP1B1 but decreased mRNA expression of IL-17, IL-22 and FOXP3 mRNA in PBMCs. B cells, CD4+ cells and Treg
proportions were significantly reduced by this treatment, but remaining CD4+ T cells were enriched in FOXP3+ cells and in
CD39-expressing Tregs.
Conclusions: In addition to the decrease in circulating CD4+ T cells and CD19+ B cells, our findings highlight additional
immunoregulatory mechanisms induced by fingolimod.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of the
central nervous system (CNS) characterized by demyelination and
neurodegeneration. A key event in MS pathogenesis is the
peripheral activation of autoreactive lymphocytes. These cells
damage the blood-brain barrier (BBB), enter the CNS and cause
local inflammation.
Disease-modifying treatments are designed to slow down disease
progression by reducing the relapse rate and the accumulation of
new lesions on MRI. Fingolimod (Gilenya, Novartis), a sphingo-
sine analogue, was the first once-daily oral drug approved for the
treatment of relapsing-remitting MS (RRMS). Both sphingosine
and fingolimod are phosphorylated to their active forms by
intracellular sphingosine kinases. Phosphorylated fingolimod
(fingolimod-P) mimics the activity of sphingosine-1-phosphate
(S1P) and acts as an agonist on 4 out of its 5 receptors [1]. Thanks
to their S1P receptors, acting as sensors, lymphocytes follow the
S1P gradient to exit secondary lymphoid organs and reach the
blood flow. Prolonged binding of fingolimod-P to its receptors
induces their internalization and degradation [2]. Fingolimod
therefore reversibly retains most lymphocytes subsets within the
lymph nodes. In MS patients, fingolimod reduces the proportion
of pro-inflammatory T helper (Th) cells producing interleukin-17
(IL-17), in the circulating blood [3]. The effects of fingolimod on T
regulatory cells (Tregs) are still incompletely described. Animal
studies have shown that fingolimod induces the conversion of
CD4+FOXP3- cells into CD4+FOXP3+ cells [4,5]. In contrast, one
report supports that fingolimod decreases the immunosuppressive
activity of Tregs in the context of graft-versus-host disease [6].
CD4+CD25hiFOXP3+ regulatory T cells are a subset of cells
specialized in the suppression of activation and proliferation of
effector T cells. Therefore, this subset is of particular importance
in limiting autoimmunity. Tregs are characterized by the
expression of the cellular marker CD25 and the transcription
factor FOXP3. However, in humans, these two markers are not
specific for Tregs as they are also expressed on effector T cells after
stimulation. Therefore, it remains uneasy to distinguish natural
Tregs and recently activated T cells. Analysing the methylation
status of the FOXP3 locus might be of particular interest to
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quantify these cells. Indeed, the first intron of FOXP3 (FOXP3i1)
shows complete demethylation in natural Tregs (nTregs) [7].
CD39 is an immunoregulatory molecule expressed by effector/
memory-like Tregs (TREM) that decreases the extracellular level of
ATP, converting it into AMP [8]. Under certain conditions, its
expression can be regulated by the transcription factor Aryl
Hydrocarbon Receptor (AHR) [9]. CD39-expressing Tregs are of
particular interest in MS as they have been shown to specifically
inhibit Th17 cells [10].
The aim of our study was to investigate the effects of fingolimod
on pro- and anti-inflammatory Th17- and Treg-related immune
markers, by analysing their ex vivo expression profile in treated
MS patients. We then analysed the effects of fingolimod therapy
on the proportions of various cell subsets, notably of CD39-
expressing cells.
Materials and Methods
Subjects and sample collection
Blood samples were obtained from 16 patients with RRMS
before starting fingolimod therapy, and after 3 months of
treatment (0.5 mg daily). The study was approved by the local
ethics committee and written informed consent was obtained from
all patients. Peripheral blood mononuclear cells (PBMCs) were
also collected from ten age- and sex-matched healthy controls
(HC). Basic demographic features are summarized in Table S1. All
patients displayed the expected lymphocyte count reduction three
months after starting fingolimod treatment.
Methylation Specific-qPCR (MethylS-qPCR) for FOXP3i1
Genomic DNA (gDNA) was prepared from frozen pellets
containing 106 total PBMCs with the PureLink DNA Mini Kit
(Invitrogen). One mg of gDNA was treated with sodium bisulfite
using the EpiTect Plus DNA Bisulfite Kit (Qiagen). Real-Time
PCR amplification of methylated and demethylated FOXP3i1
sequences was performed in a final volume of 25 ml with the
Rotor-Gene Probe PCR Kit (Qiagen), 300 nM of each primer and
100 mM of probe in a 72-well rotor on Rotor-Gene PCR 6000
Realtime Analyser (Corbett Life Science). Two-step thermal
cycling was started with a first denaturation at 95uC for 3 minutes
followed by 45 cycles at 95uC for 3 seconds and 64uC for 30
seconds. Sequences of primers and probes are indicated in Table
S2. The percentage of demethylated sequences is calculated as
follows: 2‘(Ct methylated 2Ct demethylated)/[2‘(Ct methylated
2Ct demethylated)+1]*100.
Fluorescence activated cell sorting (FACS)
Thawed PBMCs were resuspended in PBS with 1% foetal calf
serum and 2 mM EDTA. Cells were stained for surface antigens
with anti-human CD4 (eBioscience), CD8, CD19, CD39 and
CD25 (BioLegend) antibodies, then fixed and permeabilized
overnight prior to FOXP3 staining (clone 236A/E7, eBioscience).
Lymphocytes were gated according to their FSC/SSC (forward/
side scatter) profile. Median fluorescent intensity (MFI) was
analysed on the FOXP3 channel for CD4+ cells and on the
CD39 channel for CD4+CD25hiFOXP3+ cells. Acquisition was
performed on a BD LSR Fortessa instrument (BD Biosciences). All
data were analysed using FlowJo software (Tree Star Inc.).
Conditions were assayed in duplicate.
cDNA analysis and qPCR experiments
RNA from PBMCs was isolated using the miRNeasy mini kit
(Qiagen) according to the manufacturer’s protocol and reverse
transcribed to cDNA using Superscript Reverse Transcriptase
(Invitrogen). Quantitative PCR (qPCR) assays were performed
using Absolute qPCR SYBR Green mix (Thermo Scientific) on a
Rotor-Gene 6000 (Corbett Life Science). The relative amount of
transcripts was determined by normalizing for Abelson gene (ABL)
using the comparative Ct method (22DDCt) [11]. Results are
expressed relative to the mean of the healthy control patients (HC)
set at 1. Sequences of primers are detailed in Table S3.
Statistical analysis
Statistical analysis was performed using the GraphPad Prism 5
software. To test for differences before and after ivMP treatment, a
non-parametric Wilcoxon’s signed rank test was performed. MS
patients and HC were compared using the non-parametric Mann
Whitney test. P-values #0.05 were considered as statistically
significant.
Results
Ex vivo mRNA expressions of IL-17, IL-22, CD39, FOXP3,
AHR and CYP1B are affected by fingolimod in PBMC
In comparison to HC, the only significant difference was an
increase of CD39 mRNA level in MS patients (Figure 1). Indeed,
median mRNA level was 70% higher in MS patients (p = 0.0002).
The mRNA expression levels of CD39 (p = 0.0033), as well as of
AHR (p= 0.007) and CYP1B1, an AHR-induced gene (p,0.0001)
were increased after fingolimod treatment. On the contrary,
fingolimod reduced the mRNA levels of IL-17, IL-22 and FOXP3.
The most dramatic decrease was observed for IL-17 mRNA,
which was undetectable after therapy in most patients (n = 11/16)
(p = 0.024).
CD4+ T and B cell proportions are reduced in circulating
lymphoid cells after fingolimod treatment
As fingolimod inhibits the egress of lymphocytes from lymph
nodes, we wanted to further quantify cellular subsets present in
PBMCs. The proportion of B cells, characterised by the CD19
surface marker, was reduced by 50% with fingolimod treatment
(p = 0.0012). Before therapy, CD19+ B cells represented 11.45% of
the circulating lymphoid cells. This proportion was reduced to
5.9% under treatment (Figure 2, Table 1). In contrast, the
proportion of CD8+ T cells did not show a significant decrease.
Fingolimod decreased the proportion of CD4+ T cells by 7-fold
(p = 0.0006) (Figure 2). Before treatment, CD4+ T cells accounted
for 46% of the circulating lymphoid cells, but only for 6.5% after
three months of fingolimod therapy. In contrast, the proportion of
FOXP3-expressing CD4+ cells was increased in 12 out of 16
patients (p = 0.04, Figure 3A). This was associated with a median
increase of 40% in the FOXP3 MFI values (p = 0.0005, Fig. 3B).
Regulatory T cells proportion is decreased in PBMCs after
fingolimod treatment
As regulatory T cells play a central role in maintaining self-
tolerance, we then analysed the Treg proportion within total
PBMCs or CD4+ T cells. Natural Tregs were quantified by
analysing the epigenetic status of the first intron of FOXP3 using
methylation specific PCR (Figure 4A). CD4+CD25hiFOXP3+
Treg phenotype was also examined by flow cytometry (Figure 4B).
Using both MethylS-qPCR (p= 0.041) and flow cytometry
(p = 0.0029), we showed that the proportion of Tregs among total
PBMCs was decreased by the treatment. However, the proportion
of CD25hiFoxp3+ Tregs within the CD4+ cell population increased
in 12 patients out of 16 (Figure 4C, Table 1). Only 3 patients
displayed a reduction in their Treg proportion while on treatment
Increase in CD39-Expressing T Regulatory Cells by Fingolimod
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by fingolimod and one patient did not show change in this
parameter.
CD39+ Tregs increase after fingolimod
CD39+ Tregs have been shown to specifically inhibit IL-17
producing cells. Since Th17 cells exert pathogenic effect in MS, we
quantified CD39+ Tregs after treatment by fingolimod. The
proportion of CD39-expressing CD4+CD25hiFOXP3+ Tregs was
Figure 1. Ex vivo mRNA expression in total PBMCs from fingolimod-treated patients. Scatter dot plots show relative mRNA expression
levels in PBMCs from MS patients before (t0) or after 3 months (t3) of treatment by fingolimod, and healthy controls (HC) analysed by q-PCR. For each
target, individual mRNA levels were expressed as relative values to the mean level of the control group. The mRNA expression levels of CD39
(p = 0.0033), as well as of AHR (p = 0.007) and CYP1B1, an AHR-induced gene (p,0.0001) were increased after fingolimod treatment. On the contrary,
fingolimod reduced the mRNA levels of IL-17, IL-22 and FOXP3. Horizontal lines represent the median value in all subgroups. *, ** and *** indicate p-
values of #0.05, #0.01 and #0.001 respectively.
doi:10.1371/journal.pone.0113025.g001
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increased in MS patients in comparison to HC (43.4% versus
26.9%; p= 0.009). After three months of fingolimod treatment, the
proportion of CD39+ Tregs further increased from 43.4% to
76.2%, representing a median increase of 77%. This was
associated with an increase in the MFI of CD39 (Figure 5A and
5B and Table 1). The proportion of CD4+FOXP3-CD39+ cells
was affected to a lesser extent after fingolimod treatment rising
from 5.1% to 7.2% (median increase of 41%). On the contrary,
within the CD8+ and CD19+ populations, the proportion of
CD39+ cells and the CD39 MFI were not increased by the
treatment (Figure S1).
Discussion
MS is a demyelinating disease of the CNS thought to be
mediated in part by autoreactive lymphocytes. The role of
proinflammatory responses in MS has been largely investigated
and the implication of the Th17 lineage has been demonstrated in
animal and human studies [12–14]. Fingolimod has been
approved as a disease-modifying drug in the treatment of RRMS.
Fingolimod may participate to various immunoregulatory pro-
cesses other than lymphocytes retention as the S1P1 signalling is
involved in many other physiological responses [15].
Here, we show that fingolimod significantly reduces the mRNA
level of IL-17 in total PBMCs. This result is in agreement with the
finding that fingolimod decreases the amount of circulating IL-17
producing cells [3]. A similar effect is shown for IL-22. This IL-10
cytokine family member plays both protective and pathogenic
roles in autoimmune diseases but its involvement in MS is still
matter of debate. [16–18] IL-22 is not crucial in the development
of the murine experimental model of MS [19]. However,
IL22RA2 is a susceptibility gene for MS [20,21].
Interestingly, mRNA levels of CD39, AHR and CYP1B1, an
AHR-induced gene are increased in fingolimod-treated patients.
CD39 is an ectonucleotidase that hydrolyses ATP to AMP. Since
ATP acts as an inducer of proinflammatory cytokines, its cleavage
has anti-inflammatory consequences [22]. CD39 has been
described as a novel functional marker of regulatory effector/
memory-like T (TREM) cells [8]. AHR is a member of the family of
basic helix-loop-helix transcription factors. Upon binding of
exogenous agents, AHR mediates transcriptional responses of a
wide variety of genes, named AHR gene battery, which includes
CYP1B1 [23]. AHR has also been demonstrated to influence the
expression of IL-22 and CD39 [9,24]. In this study, we show an
increase in the mRNA expression levels of CD39 and CYP1B1.
Thus, AHR activation might be an additional anti-inflammatory
mechanism induced by fingolimod. AHR activation was shown to
exacerbate or to suppress EAE depending on its ligand [24,25].
EAE suppression by AHR was associated with expansion of Treg
cells. Therefore, the effects of fingolimod on AHR might have
functional relevance, in addition to its effects on the redistribution
of circulating immune cells.
We have also shown that the ex vivo levels of FOXP3 mRNA in
PBMCs are drastically reduced in contrast to the increase in the
Figure 2. Circulating T and B cell proportions in patients treated by fingolimod. PBMCs of MS patients before (t0, n = 16) or after three
months of treatment by fingolimod (t3, n = 16) and healthy controls (HC, n = 10) were analysed ex vivo by flow cytometry. The percentage of (A)
CD19+ B cells, (B) CD8+ and (C) CD4+ T cells within lymphoid cells is shown. The proportion of B cells and CD4+ T cells decreased after fingolimod
while the proportion of CD8+ T cells was not significantly modified. The horizontal lines represent the median value in all subgroups. *, ** and ***
indicate p-values of #0.05, #0.01 and #0.001 respectively.
doi:10.1371/journal.pone.0113025.g002
Table 1. Immune cell subpopulations in MS patients before (t0) or after three months of fingolimod treatment (t3) and healthy
controls analysed by ex vivo flow cytometry.
t0 t3
p-value
(t0 vs t3) HC
p-value
(t0 vs HC)
CD4 (%of lymphoid cells) 46.03 (17.2–69.6) 6.4 (1.7–48.5) 0.0006 47.3 (32.3–60.6) 0.770
CD8 (%of lymphoid cells) 20.1 (6.2–39.4) 15.18 (4.9–41.1) 0.4851 21.73 (14.7–31.5) 0.544
CD19 (%of lymphoid cells) 11.45 (3.6–25.7) 5.9 (1.8–15.25) 0.0012 7.36 (4.7–16.5) 0.025
FOXP3+ (%of CD4+) 7.92 (3.46–11.2) 11.78 (1.35–20.6) 0.0411 5.45 (2.93–10.6) 0.087
CD4+CD25hiFOXP3+ (%of lymphoid cells) 3.2 (1.67–8.26) 0.68 (0.06–4.34) 0.0029 2.63 (1.98–5.01) 0.580
CD25hiFOXP3+ (%of CD4+) 8.33 (3.73–11.9) 11.45 (1.17–19.75) 0.0929 6.27 (4.4–10.95) 0.087
CD39+ (%of CD4+CD25hiFOXP3+) 43.4 (17.9–77.3) 76.2 (29.9–93.6) 0.0005 26.9 (10.1–53.15) 0.0425
The median and range are shown. Lymphoid cells were gated according to their FSC/SSC profile.
doi:10.1371/journal.pone.0113025.t001
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proportion of FOXP3+ cells within CD4+ T cells in fingolimod-
treated patients. FOXP3 is the transcription factor of Tregs but is
also transiently expressed upon activation of effector T cells.
Therefore, its decreased mRNA level is likely due to the large
reduction of CD4+ cell count observed by flow cytometry. Indeed,
in agreement with previous studies, CD4+ and B cells proportions
are decreased by fingolimod while CD8+ T cells are less affected
[26,27]. This is consistent with the observation that TEM cells,
which are mainly CD8+ cells, are not retained in lymph nodes in
the presence of fingolimod, in contrast to TCM cells, which are
predominantly CD4+ cells [28].
Divergent findings have been published regarding the effects of
fingolimod on the proportion of Tregs [29,30]. Due to the lack of
specific cell surface Treg markers in humans, we used FOXP3i1
demethylation to assess the effect of fingolimod on circulating
natural Tregs. By flow cytometry, we confirm that the proportion
of Tregs within lymphoid cells is reduced by fingolimod. However,
the proportion of CD25hiFoxp3+ cells within the CD4+ subpop-
ulation increases in 12 treated patients out of 16. It has been
suggested that fingolimod induces FOXP3 expression in
CD4+FOXP3- T cells and causes an increase in FOXP3+ Treg
cells [4,5]. Here, we show an increase in the proportion of
FOXP3+ cells within the CD4+ cell population, as well as an
increase in median FOXP3 expression level, as indicated by higher
MFI values.
Beneficial effects of fingolimod might be additionally mediated
by modulating the function of Tregs. In order to investigate this,
we analysed the expression of CD39 by Tregs. The proportion of
CD39+ Tregs is significantly increased by fingolimod. Surface
expression of CD39 in Tregs is also increased by the treatment. It
has been suggested that CD39+ Tregs specifically inhibit Th17
cells. Therefore, their increased number might be an additional
mechanism by which fingolimod attenuates inflammation and
mediates its therapeutic benefits.
In summary, we have shown that CD39, AHR and CYP1B1
mRNA levels are increased in PBMCs following fingolimod
treatment while IL-17 mRNA is decreased. Fingolimod induces a
large decrease of B and CD4+ cells but remaining CD4+ T cells are
enriched in FOXP3+ cells. Furthermore, the proportion of CD39-
expressing Tregs within the CD4+ subpopulation is increased by
the treatment, thereby possibly providing an additional therapeu-
tic benefit of this drug. Indeed, apart from its effects on
lymphocyte egress from lymph nodes, experimental data points
towards an effect of fingolimod on Treg development. Signalling
through the S1P1 receptor has been shown to inhibit Foxp3+ Treg
differentiation, by down-regulating SMAD3 activity [31]. This
consequently counteracts TGF-b receptor-mediated signalling,
Figure 3. FOXP3 expression by CD4+ T cells of fingolimod-treated MS patients before (t0, n=16) or after three months of treatment
by fingolimod (t3, n=16) and healthy controls (HC, n=10) analysed ex vivo by flow cytometry. (A) The percentage of FOXP3-expressing
CD4+ cells was increased in 12 out of 16 patients and associated with an increase (B) of FOXP3 MFI values. * and *** indicate p-values of #0.05 and#
0.001 respectively.
doi:10.1371/journal.pone.0113025.g003
Figure 4. Regulatory T cells in PBMCs of fingolimod-treated patients. Regulatory T cells of MS patients before (t0, n = 16) or after three
months of treatment by fingolimod (t3, n = 16) and healthy controls (HC, n = 10) were analysed ex vivo by MethylS-qPCR (A) to quantify nTregs with
demethylated FOXP3i1. The proportion of circulating CD4+CD25hiFOXP3+ Tregs was also measured by flow cytometry and expressed as a percentage
of lymphoid cells (B). The proportion of CD25hiFOXP3+ cells was also expressed as a percentage of CD4+ T cells (C). nTreg proportion among total
PBMCs was decreased by the treatment, as well as the proportion of Tregs within lymphoid cells. CD25hiFOXP3+ Tregs were however enriched within
the CD4+ cell population in 12 out of 16 patients. The horizontal lines represent the median value in all subgroups. ** indicates a p-value of #0.01.
doi:10.1371/journal.pone.0113025.g004
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which is required for Treg differentiation. Inhibition of S1P1
signalling by fingolimod might therefore regulate the balance
towards Treg development, as observed in our study. It has also
been shown that treatment with fingolimod induces TGF-b in
splenocyte cell cultures, which could also be a mechanism involved
in the increased proportion of CD39-expressing Tregs in
fingolimod-treated patients [32]. Finally, our data showing an
induction of CYP1B1 mRNA following treatment by fingolimod
suggests that AHR, another transcription factor involved in Treg
differentiation and CD39 expression is activated, providing an
alternative hypothesis for our observations [9,25]. Studies are
ongoing regarding the mechanisms by which fingolimod induces
CD39-expressing cells.
Supporting Information
Figure S1 CD39-expressing cells within other cell subpopula-
tions. CD39 expression was analysed by flow cytometry in
CD4+FOXP3- T cells (A), CD19+ B cells (B) and CD8+ T cells
(C). The proportion of CD4+FOXP3-CD39+ cells increases slightly
following treatment by fingolimod. The treatment did not increase
the proportion of CD39+ cells within the CD8+ and CD19+
populations. The horizontal lines represent the median value in all
subgroups. * and ** indicate p-values of #0.05 and #0.01
respectively.
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